System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review English Abstract Ppublish

PubMed: 42083845

[Steatosis and steatohepatitis: a risk factor for complications after liver resection].

Rev Prat 76(4):413-417

Authors: Karim Boudjema, Fabien Robin, Heithem Jeddou, Pauline Houssel-Debry

Affiliations

  • Faculté de médecine de Rennes, université de Rennes, membre de l'Académie nationale de médecine, France.
  • Service de chirurgie hépatobiliaire et digestive, CHU de Rennes, Rennes, France.
  • Service des maladies du foie, CHU de Rennes, Rennes, France.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), have become common clinical conditions in everyday practice. Long regarded as benign, they can lead to serious liver complications, including cirrhosis and hepatocellular carcinoma, which may require liver resection or, in selected cases, liver transplantation.The presence of steatosis or steatohepatitis increases the risk of postoperative complications after hepatic resection. In the transplant setting, MASH is an increasingly frequent indication and is reshaping the management of liver transplant recipients, who often have associated metabolic syndrome (obesity, diabetes, hypertension). After transplantation, recurrence of steatosis in the graft is almost inevitable, likely reflecting the persistence of underlying genetic and environmental factors that drive metabolic syndrome.At the same time, the rising prevalence of steatosis in the general population also affects organ donors, potentially impairing graft quality and complicating post-transplant management.The growing burden of MASLD and MASH therefore calls for close collaboration between hospital-based specialists and primary care physicians, particularly for screening, management of metabolic risk factors, and long-term follow-up of patients who have undergone liver surgery or transplantation.

MeSH

Liver Transplantation, Non-Alcoholic Fatty Liver Disease, Liver, Risk Factors, Transplants, Metabolic Syndrome, Transplantation